In July 2020, Stephen Eck, M.D., Ph.D., joined MacroGenics as its Senior Vice President for Clinical Development and Chief Medical Officer. Prior to MacroGenics, Dr. Eck served as chief medical officer of Immatics U.S., a company focused on TCR-based immunotherapies, and as president and CEO of Aravive Biologics.
Prior to these roles, Dr. Eck was Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma, managing a portfolio of assets that included enzalutamide (Xtandi®), erlotinib (Tarceva®), and gilteritinib (Xospata®). Dr. Eck has also held leadership positions in drug development as Vice President of Translational Medicine and Pharmacogenomics at Eli Lilly and as Head of Clinical Oncology at Pfizer. He began his professional career at Monsanto in cancer target discovery and later joined the University of Pennsylvania, where he was the Anne B. Young Assistant Professor of Cancer Research and the Director of the Cancer Gene Therapy Program.
